The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin

doi:10.1016/0006-291X(87)90430-X

Biochemical and Biophysical Research Communications

Volume 149, Issue 2, 16 December 1987, Pages 744-749

https://doi.org/10.1016/0006-291X(87)90430-X Get rights and content

Abstract

Three proteins (31, 35 and 39kDa) with inhibin-like activity have been isolated from bovine follicular fluid with identical NH₂-terminal amino acid sequences. These polypeptides are distinct from inhibin, based on their different NH₂-amino acid sequence, molecular masses, absence of a subunit structure, absence of inhibin immunoactivity and the failure of inhibin antiserum to neutralize their bioactivity $in vitro$ . Their inhibin-like biological activities based on their ability to suppress FSH cell content by pituitary cells in culture are 5–10% of bovine 31kDa inhibin.

References (19)

R.I. McLachlan et al.
Bailliere's Clin. Endocrinol. and Metab
(1987)
Y. Eto et al.
Biochem. Biophys. Res. Commun
(1987)
R.L. Cate et al.
Cell
(1986)
D.M. Robertson et al.
Mol. Cell Endocrinol
(1986)
M.W. Hunkapiller et al.
Methods. Enzymol
(1983)
C.L. Zimmerman et al.
J. Anal. Biochem
(1977)
R.I. McLachlan et al.
Mol. Cell. Endocrinol
(1986)
W. Vale et al.
Nature
(1986)
N. Ling et al.
Nature
(1986)

There are more references available in the full text version of this article.

Cited by (307)

Follistatin and follistatin-like 3 in metabolic disorders
2023, Prostaglandins and Other Lipid Mediators
Follistatin (FST) is a glycoprotein which main role is antagonizing activity of transforming growth factor β superfamily members. Folistatin-related proteins such as follistatin-like 3 (FSTL3) also reveal these properties. The exact function of them has still not been established, but it can be bound to the pathogenesis of metabolic disorders. So far, there were performed a few studies about their role in type 2 diabetes, obesity or gestational diabetes and even less in type 1 diabetes. The outcomes are contradictory and do not allow to draw exact conclusions. In this article we summarize the available information about connections between follistatin, as well as follistatin-like 3, and metabolic disorders. We also emphasize the strong need of performing further research to explain their exact role, especially in the pathogenesis of diabetes and obesity.
Crosstalk between the liver and kidney in diabetic nephropathy
2022, European Journal of Pharmacology
Diabetic nephropathy (DN) is a serious complication of diabetes, and its pathogenesis has not been fully elucidated. Recently, communication between organs has gradually become a new focus in the study of diseases pathogenesis, and abnormal interorgan communication has been proven to be involved in the occurrence and progression of many diseases. As an important metabolic organ in the human body, the liver plays an important role in maintaining homeostasis in humans. The liver secretes a series of proteins called hepatokines that affect adjacent and distal organs through paracrine or endocrine signaling pathways. In this review, we summarize some of the hepatokines identified to date and describe their roles in DN to discuss the possibility that the liver-renal axis is potentially useful as a therapeutic target for DN. We summarize the important hepatokines identified thus far and discuss their relationship with DN. We propose for the first time that the “liver-renal axis” is a potential therapeutic target in individuals with DN.
Strategic structure–activity relationship study on a follistatin-derived myostatin inhibitory peptide
2021, Bioorganic and Medicinal Chemistry Letters
Myostatin, a negative regulator of muscle mass is a promising target for the treatment of muscle atrophic diseases. The novel myostatin inhibitory peptide, DF-3 is derived from the N-terminal α-helical domain of follistatin, which is an endogenous inhibitor of myostatin and other TGF-β family members. It has been suggested that the optimization of hydrophobic residues is important to enhance the myostatin inhibition. This study describes a structure–activity relationship study focused on hydrophobic residues of DF-3 and designed to obtain a more potent peptide. A methionine residue in DF-3, which is susceptible to oxidation, was successfully converted to homophenylalanine in DF-100, and a new derivative DF-100, with four amino acid substitutions in DF-3 shows twice the potent inhibitory ability as DF-3. This report provides a new platform of a 14-mer peptide muscle enhancer.
Follistatin
2021, Handbook of Hormones: Comparative Endocrinology for Basic and Clinical Research
Follistatin is a monomeric glycoprotein structurally unrelated to inhibin and activin. There are three alternatively spliced products of the single follistatin gene: follistatin 288, follistatin 303, and follistatin 315. Follistatin 288 lacks the carboxyl-terminal acidic region of follistatin 315. Additionally, follistatin-like 3 (follistatin-related protein) is identified, which has a similar structure to follistatin. Follistatin is generally coexpressed with activin and most highly expressed in the ovary and pituitary, but also in a variety of cells and tissues. Follistatin binds activin with high affinity and nullifies its biological actions by preventing its binding and subsequent activation of type I and II activin receptors. This chapter briefly introduces the structure of the follistatin family and its biological functions in relation to the pluripotent effects of activin.
Discovery of a follistatin-derived myostatin inhibitory peptide
2020, Bioorganic and Medicinal Chemistry Letters
Follistatin is well known as an inhibitor of transforming growth factor (TGF)-β superfamily ligands including myostatin and activin A. Myostatin, a negative regulator of muscle growth, is a promising target with which to treat muscle atrophic diseases. Here, we focused on the N-terminal domain (ND) of follistatin (Fst) that interacts with the type I receptor binding site of myostatin. Through bioassay of synthetic ND-derived fragment peptides, we identified DF-3, a new myostatin inhibitory 14-mer peptide which effectively inhibits myostatin, but fails to inhibit activin A or TGF-β1, in an in vitro luciferase reporter assay. Injected intramuscularly, DF-3 significantly increases skeletal muscle mass in mice and consequently, it can serve as a platform for development of muscle enhancement based on myostatin inhibition.
Molecular cloning, expression pattern of follistatin gene and association analysis with growth traits in bighead carp (Hypophthalmichthys nobilis)
2018, Comparative Biochemistry and Physiology Part - B: Biochemistry and Molecular Biology
Citation Excerpt :
Follistatin (FST) is a monomeric glycoprotein rich in cysteine, originally isolated from bovine and porcine follicular fluid in 1987 (Robertson et al., 1987; Ueno et al., 1987).
Follistatin (FST) is a single-chain gonadal protein involving in various biological effects. FST plays important roles in not only ovary development but also body growth, whereas myostatin (MSTN) negatively regulates muscle growth. In this study, FST gene in bighead carp (HynFST) was cloned and characterized. A 5797 bp genomic sequence of HynFST, consisting six exons and five introns were cloned. The full-length cDNA of HynFST (2134 bp) has an open reading fragment encoding a polypeptide of 349 amino acids. Sequence comparison and phylogenetic analysis confirmed that FSTs are conserved throughout the vertebrates and HynFST belongs to FST-1 isoform. Nine single nucleotide polymorphisms (SNPs) of the HynFST were identified and three of them (g.2443 T > C, g.2852 T > C and g.5483A > G) were significantly associated with four growth-related traits. The average body weight of those fish with the combined genotype (CC CC GG) was 12.15–22.63% higher than that of triplotype (TT TT AA) in two bighead carp populations. HynFST was expressed in most of the development stages and various tissues with highest level in ovary. The co-expression results for FST and MSTN in brain and muscle of divergent weight groups showed that FST may inhibit MSTN expression, thus enhancing growth in bighead carp. Our results suggest that FST has significant genetic effects on the regulation of early growth in bighead carp. This study would facilitate the elucidation of multiple functions of FST gene in fish and exploration of the potentials as a gene marker in selective breeding programs for growth of bighead carp.

View all citing articles on Scopus

View full text

The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin

Abstract

Bailliere's Clin. Endocrinol. and Metab

Biochem. Biophys. Res. Commun

Cell

Mol. Cell Endocrinol

Methods. Enzymol

J. Anal. Biochem

Mol. Cell. Endocrinol

Nature

Nature